Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Pancreatic Neoplasms 26Urinary Bladder Neoplasms 17Carcinoma, Non-Small-Cell Lung 17Lung Neoplasms 13Ovarian Neoplasms 10Nasopharyngeal Carcinoma 9Biliary Tract Neoplasms 8Non-Muscle Invasive Bladder Neoplasms 7Neoplasm Metastasis 7Cholangiocarcinoma 7Lymphoma, Large B-Cell, Diffuse 6Triple Negative Breast Neoplasms 5Colorectal Neoplasms 5Breast Neoplasms 5Recurrence 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4Neoplasms 4Fallopian Tube Neoplasms 4Endometrial Neoplasms 4Carcinoma, Transitional Cell 4Osteosarcoma 3Melanoma 3Lymphoma, Non-Hodgkin 3Uterine Cervical Neoplasms 2Urologic Neoplasms 2Rectal Neoplasms 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Gallbladder Neoplasms 2Colonic Neoplasms 2

Interventions

toripalimab 1spartalizumab 1Surveys and Questionnaires 1Gemcitabine 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Nasopharyngeal Neoplasms × Gemcitabine × 30 days × Clear all
NCT06802835 2026-05-11

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 1/2 Recruiting
148 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡